Eli Lilly (LLY) R&D In Process (2016 - 2025)
Eli Lilly (LLY) has disclosed R&D In Process for 16 consecutive years, with $518.8 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, R&D In Process rose 148.47% year-over-year to $518.8 million, compared with a TTM value of $2.9 billion through Dec 2025, down 12.12%, and an annual FY2025 reading of $2.9 billion, down 12.12% over the prior year.
- R&D In Process was $518.8 million for Q4 2025 at Eli Lilly, down from $655.7 million in the prior quarter.
- Across five years, R&D In Process topped out at $3.0 billion in Q3 2023 and bottomed at $25.0 million in Q2 2021.
- Average R&D In Process over 5 years is $614.8 million, with a median of $254.0 million recorded in 2021.
- Peak annual rise in R&D In Process hit 4667.79% in 2023, while the deepest fall reached 77.95% in 2023.
- Year by year, R&D In Process stood at $471.8 million in 2021, then soared by 39.15% to $656.5 million in 2022, then dropped by 5.13% to $622.8 million in 2023, then tumbled by 66.47% to $208.8 million in 2024, then surged by 148.47% to $518.8 million in 2025.
- Business Quant data shows R&D In Process for LLY at $518.8 million in Q4 2025, $655.7 million in Q3 2025, and $155.5 million in Q2 2025.